Expression of leukemia-associated fusion proteins increases sensitivity to histone deacetylase inhibitor-induced DNA damage and apoptosis

Molecular Cancer Therapeutics

Volumn 12, Issue 8, 2013, Pages 1591-1604

  Petruccelli, Luca A ^a   Pettersson, Filippa ^a   Del Rincon, Sonia V ^a   Guilbert, Cynthia ^a   Licht, Jonathan D ^b   Miller Jr , Wilson H ^a  

^a MCGILL UNIVERSITY   (Canada)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; HYBRID PROTEIN; PROMYELOCYTIC LEUKEMIA PROTEIN; PROMYELOCYTIC LEUKEMIA PROTEIN RETINOIC ACID RECEPTOR ALPHA; PROTEIN BCL 2; PROTEIN PLZF RETINOIC ACID RECEPTOR ALPHA; RETINOIC ACID RECEPTOR ALPHA; TRANSCRIPTION FACTOR RUNX1; TRANSCRIPTION FACTOR RUNX1 ETO; UNCLASSIFIED DRUG; VORINOSTAT;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; ARTICLE; CELL DEATH; CONTROLLED STUDY; DNA DAMAGE; DNA REPAIR; DOUBLE STRANDED DNA BREAK; DOWN REGULATION; DRUG RESPONSE; EXCISION REPAIR; G2 PHASE CELL CYCLE CHECKPOINT; LEUKEMIA CELL LINE; M PHASE CELL CYCLE CHECKPOINT; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; DNA DAMAGE; DNA REPAIR; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, LEUKEMIC; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; LEUKEMIA, MYELOID, ACUTE; ONCOGENE PROTEINS, FUSION;

EID: 84882252095     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-12-1039     Document Type: Article

References (51)

1. Kelly LM, Gilliland DG. Genetics of myeloid leukemias. Annu Rev Genomics Hum Genet 2002;3:179-98.
2. Melnick A, Licht JD. Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood 1999;93:3167-215.
3. Elagib KE, Goldfarb AN. Oncogenic pathways of AML1-ETO in acute myeloid leukemia: Multifaceted manipulation of marrow maturation. Cancer Lett 2007;251:179-86.
4. Marks PA. The clinical development of histone deacetylase inhibitors as targeted anticancer drugs. Expert Opin Investig Drugs 2010;19: 1049-66.
5. Cote S, Rosenauer A, Bianchini A, Seiter K, Vandewiele J, Nervi C, et al. Response to histone deacetylase inhibition of novel PML/RARalpha mutants detected in retinoic acid-resistant APL cells. Blood 2002;100: 2586-96.
6. He LZ, Tolentino T, Grayson P, Zhong S, Warrell RP Jr., Rifkind RA, et al. Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia. J Clin Invest 2001;108:1321-30.
7. Mann BS, Johnson JR, Cohen MH, Justice R, Pazdur R. FDA approval summary: Vorinostat for treatment of advanced primary cutaneous Tcell lymphoma. Oncologist 2007;12:1247-52.
8. Alcalay M, Meani N, Gelmetti V, Fantozzi A, Fagioli M, Orleth A, et al. Acute myeloid leukemia fusion proteins deregulate genes involved in stem cell maintenance and DNA repair. J Clin Invest 2003;112: 1751-61.
9. Nowicki MO, Falinski R, Koptyra M, Slupianek A, Stoklosa T, Gloc E, et al. BCR/ABL oncogenic kinase promotes unfaithful repair of the reactive oxygen species-dependent DNA double-strand breaks. Blood 2004;104:3746-53.
10. Sampath D, Plunkett W. The role of DNA repair in chronic lymphocytic leukemia pathogenesis and chemotherapy resistance. Curr Oncol Rep 2007;9:361-7.
11. Petruccelli LA, Dupere-Richer D, Pettersson F, Retrouvey H, Skoulikas S, Miller WH Jr. Vorinostat induces reactive oxygen species and DNA damage in acute myeloid leukemia cells. PLoS One 2011;6:e20987.
12. Chen CS, Wang YC, Yang HC, Huang PH, Kulp SK, Yang CC, et al. Histone deacetylase inhibitors sensitize prostate cancer cells to agents that produce DNA double-strand breaks by targeting Ku70 acetylation. Cancer Res 2007;67:5318-27.
13. Munshi A, Kurland JF, Nishikawa T, Tanaka T, Hobbs ML, Tucker SL, et al. Histone deacetylase inhibitors radiosensitize human melanoma cells by suppressing DNA repair activity. Clin Cancer Res 2005;11: 4912-22.
14. Rosato RR, Almenara JA, Maggio SC, Coe S, Atadja P, Dent P, et al. Role of histone deacetylase inhibitor-induced reactive oxygen species and DNA damage in LAQ-824/fludarabine antileukemic interactions. Mol Cancer Ther 2008;7:3285-97.
15. Conti C, Leo E, Eichler GS, Sordet O, Martin MM, Fan A, et al. Inhibition of histone deacetylase in cancer cells slows down replication forks, activates dormant origins, and induces DNA damage. Cancer Res 2010;70:4470-80.
16. Shubassi G, Robert T, Vanoli F, Minucci S, Foiani M. Acetylation: A novel link between double-strand break repair and autophagy. Cancer Res 2012;72:1332-5.
17. Barbetti V, Gozzini A, Rovida E, Morandi A, Spinelli E, Fossati G, et al. Selective anti-leukaemic activity of low-dose histone deacetylase inhibitor ITF2357 on AML1/ETO-positive cells. Oncogene 2008;27: 1767-78.
18. Odenike OM, Alkan S, Sher D, Godwin JE, Huo D, Brandt SJ, et al. Histone deacetylase inhibitor romidepsin has differential activity in core binding factor acute myeloid leukemia. Clinical Cancer Res 2008;14:7095-101.
19. Sugimoto K, Toyoshima H, Sakai R, Miyagawa K, Hagiwara K, Ishikawa F, et al. Frequent mutations in the p53 gene in human myeloid leukemia cell lines. Blood 1992;79:2378-83.
20. Rice KL, Hormaeche I, Doulatov S, Flatow JM, Grimwade D, Mills KI, et al. Comprehensive genomic screens identify a role for PLZF-RARalpha as a positive regulator of cell proliferation via direct regulation of c-MYC. Blood 2009;114:5499-511.
21. Ruthardt M, Testa U, Nervi C, Ferrucci PF, Grignani F, Puccetti E, et al. Opposite effects of the acute promyelocytic leukemia PML-retinoic acid receptor alpha (RAR alpha) and PLZF-RAR alpha fusion proteins on retinoic acid signalling. Mol Cell Biol 1997;17:4859-69.
22. Hollick JJ, Golding BT, Hardcastle IR, Martin N, Richardson C, Rigoreau LJ, et al. 2,6-disubstituted pyran-4-one and thiopyran-4-one inhibitors of DNA-Dependent protein kinase (DNA-PK). Bioorg Med Chem Lett 2003;13:3083-6.
23. Olive PL, Banath JP. The comet assay: A method to measure DNA damage in individual cells. Nat Protoc 2006;1:23-9.
24. Schroder HC, Batel R, Schwertner H, Boreiko O, Muller WE. Fast micromethod DNA single-strand-break assay. Methods Mol Biol 2006;314:287-305.
25. Gomes NP, Bjerke G, Llorente B, Szostek SA, Emerson BM, Espinosa JM. Gene-specific requirement for P-TEFb activity and RNA polymerase II phosphorylation within the p53 transcriptional program. Genes Dev 2006;20:601-12.
26. Duan H, Heckman CA, Boxer LM. Histone deacetylase inhibitors down-regulate bcl-2 expression and induce apoptosis in t(14;18) lymphomas. Mol Cell Biol 2005;25:1608-19.
27. Hamer G, Roepers-Gajadien HL, van Duyn-Goedhart A, Gademan IS, Kal HB, van Buul PP, et al. DNA double-strand breaks and gamma-H2AX signaling in the testis. Biol Reprod 2003;68:628-34.
28. Viale A, De Franco F, Orleth A, Cambiaghi V, Giuliani V, Bossi D, et al. Cell-cycle restriction limits DNA damage and maintains self-renewal of leukaemia stem cells. Nature 2009;457:51-6.
29. Vrana JA, Decker RH, Johnson CR, Wang Z, Jarvis WD, Richon VM, et al. Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2/Bcl-XL, c-Jun, and p21CIP1, but independent of p53. Oncogene 1999;18:7016-25.
30. Wang H, Zhou W, Zheng Z, Zhang P, Tu B, He Q, et al. The HDAC inhibitor depsipeptide transactivates the p53/p21 pathway by inducing DNA damage. DNA Repair (Amst) 2012;11:146-56.
31. Marazita MC, Ogara MF, Sonzogni SV, Marti M, Dusetti NJ, Pignataro OP, et al. CDK2 and PKA mediated-sequential phosphorylation is critical for p19INK4d function in the DNA damage response. PLoS One 2012;7:e35638.
32. Yokota T, Matsuzaki Y, Miyazawa K, Zindy F, Roussel MF, Sakai T. Histone deacetylase inhibitors activate INK4d gene through Sp1 site in its promoter. Oncogene 2004;23:5340-9.
33. Branzei D, Foiani M. Regulation ofDNArepair throughout the cell cycle. Nat Rev Mol Cell Biol 2008;9:297-308.
34. Ahn JY, Schwarz JK, Piwnica-Worms H, Canman CE. Threonine 68 phosphorylation by ataxia telangiectasia mutated is required for efficient activation of Chk2 in response to ionizing radiation. Cancer Res 2000;60:5934-6.
35. Li J, Stern DF. Regulation of CHK2 by DNA-dependent protein kinase. J Biol Chem 2005;280:12041-50.
36. Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: A changing paradigm. Nat Rev Cancer 2009;9:153-66.
37. Romanski A, Schwarz K, Keller M, Wietbrauk S, Vogel A, Roos J, et al. Deacetylase inhibitors modulate proliferation and self-renewal properties of leukemic stem and progenitor cells. Cell Cycle 2012; 11:3219-26.
38. Eapen AK, Henry MK, Quelle DE, Quelle FW. DNA damage-induced G (1) arrest in hematopoietic cells is overridden following phosphatidylinositol 3-kinase-dependent activation of cyclin-dependent kinase 2. Mol Cell Biol 2001;21:6113-21.
39. Munshi A, Tanaka T, Hobbs ML, Tucker SL, Richon VM, Meyn RE. Vorinostat, a histone deacetylase inhibitor, enhances the response of human tumor cells to ionizing radiation through prolongation of gamma-H2AX foci. Mol Cancer Ther 2006;5:1967-74.
40. Zhang Y, Carr T, Dimtchev A, Zaer N, Dritschilo A, Jung M. Attenuated DNA damage repair by trichostatin A through BRCA1 suppression. Radiat Res 2007;168:115-24.
41. Kachhap SK, Rosmus N, Collis SJ, Kortenhorst MS, Wissing MD, Hedayati M, et al. Downregulation of homologous recombination DNA repair genes byHDACinhibition in prostate cancer is mediated through the E2F1 transcription factor. PLoS One 2010;5:e11208.
42. Wilson DM III, Barsky D. The major human abasic endonuclease: Formation, consequences and repair of abasic lesions in DNA. Mutat Res 2001;485:283-307.
43. Kelley MR, GeorgiadisMM, Fishel ML. APE1/Ref-1 role in redox signaling: Translational applications of targeting the redox function of the DNA repair/redox protein APE1/Ref-1. Curr Mol Pharmacol 2012;5:36-53.
44. Xanthoudakis S, Smeyne RJ, Wallace JD, Curran T. The redox/DNA repair protein, Ref-1, is essential for early embryonic development in mice. Proc Natl Acad Sci U S A 1996;93:8919-23.
45. Huamani J, McMahan CA, Herbert DC, Reddick R, McCarrey JR, MacInnes MI, et al. Spontaneous mutagenesis is enhanced in Apex heterozygous mice. Mol Cell Biol 2004;24:8145-53.
46. Kakolyris S, Kaklamanis L, Engels K, Fox SB, Taylor M, Hickson ID, et al. Human AP endonuclease 1 (HAP1) protein expression in breast cancer correlates with lymph node status and angiogenesis. Br J Cancer 1998;77:1169-73.
47. Bobola MS, Blank A, Berger MS, Stevens BA, Silber Jr. Apurinic/apyrimidinic endonuclease activity is elevated in human adult gliomas. Clin Cancer Res 2001;7:3510-8.
48. Fishel ML, He Y, Reed AM, Chin-Sinex H, Hutchins GD, MendoncaMS, et al. Knockdown of the DNA repair and redox signaling protein Ape1/Ref-1 blocks ovarian cancer cell and tumor growth. DNA Repair (Amst) 2008;7:177-86.
49. Bapat A, Glass LS, Luo M, Fishel ML, Long EC, Georgiadis MM, et al. Novel small-molecule inhibitor of apurinic/apyrimidinic endonuclease 1 blocks proliferation and reduces viability of glioblastoma cells. J Pharmacol Exp Ther 2010;334:988-98.
50. Garcia-Manero G, Yang H, Bueso-Ramos C, Ferrajoli A, Cortes J, Wierda WG, et al. Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood 2008; 111:1060-6.
51. Schaefer EW, Loaiza-Bonilla A, Juckett M, DiPersio JF, Roy V, Slack J, et al. A phase 2 study of vorinostat in acute myeloid leukemia. Haematologica 2009;94:1375-82.